Gary Rothbard, MD, MS

Researchers found data that showed patients who have or who are injecting drugs would benefit from treatment for HCV with direct-acting antivirals.

At centers in Asia, Europe, and the Americas, investigators conducted a randomized controlled trial of patients with chronic hepatitis B virus infection to assess the long-term effects of entecavir.

Investigators found that young age, high HCV viral load, and HCV/HIV co-infection were the factors associated with an increased transmission risk.

Researchers found data that showed entecavir is safe in the treatment of hepatitis B virus in patients who are undergoing hemodialysis.

Researchers found data that showed early initiation of antiviral therapy with lamivudine in infants with hepatitis B caused a rapid loss of HBsAg.